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Abstract
Experience-dependent brain plasticity typically declines after an early critical period during which
circuits are established. Loss of plasticity with closure of the critical period limits improvement of
function in adulthood, but the mechanisms that change the brain’s plasticity remain poorly
understood. Here, we identified an increase in expression of Lynx1 protein in mice that prevented
plasticity in the primary visual cortex late in life. Removal of this molecular brake enhanced
nicotinic acetylcholine receptor signaling. Lynx1 expression thus maintains stability of mature
cortical networks in the presence of cholinergic innervation. The results suggest that modulating
the balance between excitatory and inhibitory circuits reactivates visual plasticity and may present
a therapeutic target.
The waxing and waning of cortical plasticity during a postnatal critical period serves to
consolidate neural circuits and behavior (1), but in turn limits recovery of function in the
adult brain (2). For example, discordant vision through the two eyes during an early critical
period results in the enduring loss of visual acuity (amblyopia) reflecting aberrant circuit
remodeling within primary visual cortex (V1). Amblyopia, which affects 2–4% of the
human population, exhibits little recovery in adulthood (3). Identifying specific biological
mechanisms which restrict adult plasticity would inspire potentially novel strategies for
therapy.
We hypothesized that the gradual emergence of molecular “brakes” might actively prevent
plasticity in the adult brain. The only molecules previously reported to play a role in closing
the critical period are related to axonal growth inhibition, such as chondroitin sulphate
proteoglycans and myelin-signaling proteins, NgR and PirB (4–6). To identify further
targets, we analyzed the transcriptome of the binocular zone in mouse V1 to identify
molecules that are expressed more in adulthood than during the critical period (7). Here, we
characterize one of these, lynx1, which is an endogenous prototoxin similar to α-
bungarotoxin in snake venom and binds to the nicotinic acetylcholine receptor (nAChR) (8).
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Lynx1 expression increases only after the critical period for amblyopia in adult V1 both at
the protein and mRNA level (Fig. 1A). Along the visual pathway, lynx1 transcripts were
expressed both in V1 and the lateral geniculate nucleus (LGN) (Fig. 1B). In contrast,
expression of another member of the lynx family, lynx2, declined over the critical period,
and was not found in the visual pathway (Fig. S1). We therefore directly assessed lynx1
function in the binocular region by electrophysiological recordings from knockout mice.
In mice lacking the Lynx1 gene, the eye preference of single neurons (ocular dominance)
was no different from that of wild-type mice (Fig. 1E). Upon short-term (4 day) monocular
deprivation (MD) in mature wild-type animals (> postnatal day, P60), there was little change
in the visual spiking response (3). Instead, adult lynx1 knockout mice exhibited a robust
shift in responsiveness away from the deprived eye (Fig. 1C–E). This heightened plasticity
was specific to older ages, as short-term MD was equally effective in both wild-type (WT)
and lynx1 knockout (KO) mice during the critical period (Fig. 2A).
Lynx1 protein directly binds to nAChRs (9), such as the major central subunits α4β2
heteromers or α7 homomers, to reduce their sensitivity to acetylcholine. We directly
assessed the response to systemic nicotine injection in lynx1 knockout mice by measuring
visual evoked potential (VEP) response in anesthetized V1. Enhancement of VEP response
was only observed in lynx1 knockout mice (Fig. 2B,C). To test whether nAChR signaling
mediates adult plasticity in lynx1 knockout mice, we applied the broad spectrum antagonist
mecamylamine concurrent with short-term MD. Either systemic injection or restricted
infusion directly into V1 by osmotic mini-pump were sufficient to prevent adult plasticity.
These results were corroborated by systemic treatment with a mixture of α4- and α7-subunit
selective nAChR antagonists (10), dihydro-β-eryhtroidine (DHβE) plus methyllycaconitine
(MLA) (Fig. 2A).
To establish clinical relevance of these findings, we directly measured recovery from
amblyopia in adulthood. In wild-type mice, long-term MD spanning the entire critical period
results in significant reduction of visual acuity as measured directly in V1 by VEP (3).
Notably, this reduction persists into adulthood even if the closed eye was reopened for more
than one month after the critical period (Fig. 3A,C). Dramatically, lynx1 knockout mice
spontaneously recovered visual acuity to normal levels simply by reopening the closed eye
(Fig. 3A,C), exhibiting VEPs even at higher spatial frequencies (Fig. 3B). Given the
cholinergic basis of this plasticity, we further attempted to induce recovery even in adult
wild-type mice by enhancing endogenous ACh signaling. Injection of an
acetylcholinesterase inhibitor, physostigmine, during the period of eye re-opening similarly
restored vision to wild-type mice initially rendered amblyopic (Fig. 3C).
Recovery of function in lynx1 knockout mice is likely due to an enhanced visual
responsiveness during arousal. We did not observe structural changes at the level of
perineuronal nets (4) or myelination (5) in lynx1 knockout mice (Fig. S2). Aging-related
neurodegeneration reported previously in these animals (11) was confirmed to occur only
past nine months of age. Instead, local excitatory-inhibitory circuit balance might have been
affected earlier (3) (Fig. 4A). Previous reports across various species have localized
nAChRs to thalamocortical terminals presynaptic to principal cells (12–16), facilitating
excitation in V1 (17, 18). Activation of nAChRs upon specific inhibitory neurons could
further modulate excitatory-inhibitory balance by disinhibition (19, 20), as in the case of
congenital nAChR mutation that disrupts GABAergic transmission (21).
Indeed, lynx1 and nAChRs were co-expressed not only in the LGN (Fig. S3), but also in a
sub-population of GABA cells, primarily parvalbumin-positive interneurons (Fig. 4B, S3B).
Activation of nAChRs may also exert chronic epigenetic effects on GABA synthesis (22).
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To probe whether excitatory-inhibitory imbalance may contribute to adult plasticity in
Lynx1 knockout mice, we directly restored intracortical inhibition by focal benzodiazepine
infusion from osmotic minipumps. Diazepam treatment of V1 abolished adult plasticity in
lynx1 knockout mice (Fig. 4C) as did nAChR blockade above (Fig. 2A). Thus, lynx1
reduces adult plasticity through cholinergic signaling mechanisms that may adjust
excitatory-inhibitory balance later in life (3).
Taken together, lynx1 provides both a valuable endogenous tool with which to probe critical
period closure and offers novel therapeutic and conceptual insight. In contrast to muscarinic
receptors engaged during the critical period (23), our results highlight a nicotinic component
for adult V1 plasticity. While we do not rule out a role for muscarinic receptors (24),
deletion of Lynx1 alone is sufficient to rescue visual acuity. Recovery strategies aimed at the
lynx1-nAChR interaction (8, 9) could be fruitful in conjunction with attentional tasks that
stimulate cholinergic release (e.g. perceptual learning, video game training) (25–28).
Clinically approved cholinesterase inhibitors that boost the afferent response in human
visual cortex (29) may be useful for treating some amblyopes (Fig. 3C), including those with
sub-cortical changes (30). Amblyopia might further serve as a diagnostic measure to identify
tobacco exposure (31) or schizophrenia (32).
While a permissive role for cholinergic input has long been appreciated during the critical
period (33), it has remained a mystery why V1 plasticity is severely restricted in adulthood
even in the presence of massive innervation from the basal forebrain. Lynx1 expression not
only contributes to nAChR agonist binding and desensitization kinetics (8), but also may
respond to changes in network activity (34). Local regulation of Lynx1 levels may allow
cholinergic activation to induce islands of plasticity while maintaining overall circuit
stability. Visual attention tasks in fact preferentially modulate fast-spiking inhibitory
neurons (35,36), consistent with a convergence of top-down influences upon local
excitatory-inhibitory circuit balance.
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Lynx1 increases in adulthood to limit visual plasticity. (A) Expression of lynx1 protein
(upper panel) and mRNA (lower panel) across critical period (Pre-CP: P18, CP: P28, Post-
CP: P60). **P < 0.01, *P < 0.05 One-way ANOVA. Mean ± sem. (B) In situ hybridization
of lynx1 in adult V1 (upper panel), and LGN (lower panel). Scale, 100µm. (C) Adult V1
plasticity paradigm by short-term MD (Ad-MD). (D) Ad-MD shifts the ocular dominance
distribution of lynx1 KO mice (lower panel; CBI = 0.55, 216 cells, 8 mice), but not in WT
mice (upper panel; CBI = 0.68, 231 cells, 9 mice). KO vs WT; P < 0.0001, χ2-test. (E)
Cumulative probability of quantified spike response after Ad-MD confirms shifted ocular
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dominance scores for lynx1 KO (blue filled circles) compared to WT (grey filled circles) (**
P < 0.005, K-S test) or no MD (blue open circles, KO, 93 cells; grey open circles, WT, 82
cells; P = 0.75, K-S test).
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Nicotinic receptors mediate adult plasticity in lynx1 KO mice. (A) Mice without MD (open
circles, grey KO / blue WT) shift equally after MD during the CP (light blue, KO: mean CBI
= 0.48, 6 mice; light grey, WT: CBI = 0.50, 8 mice; P > 0.5, t-test). Adult plasticity (blue,
KOMD: CBI = 0.55, 12 mice vs grey, WTMD: CBI = 0.68, 9 mice; *** P < 0.0001, t-test) is
abolished by concurrent nAChR antagonists (red, KOMD + mecamylamine: CBI = 0.68, 9
mice vs KOMD, *** P < 0.0001; vs grey, WTMD + mecamylamine: CBI = 0.69, 4 mice, P
> 0.7; vs no MD KO + mecamylamine: CBI = 0.68, 7 mice, P > 0.9, t-test; orange, KOMD +
DHβE / MLA: CBI = 0.68, 7 mice vs KOMD, *** P < 0.0001, t-test). Darker circles
represent cortical mini-pump infusion. (B) Enhanced nicotine response in lynx1 KO mice.
Averaged VEP traces (mean ± sem) before (light grey) and 10 minutes after (black)
subcutaneous nicotine injection (+ nic) in WT (left) and lynx1 KO mice (right). (C)
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Integrated VEP (area of first negative peak) for WT (empty bars, 6 mice) and lynx1 KO
mice (filled bars, 11 mice). * P < 0.05, t-test; n.s., not significant.
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Recovery from amblyopia in lynx1 KO mice. (A) After long-term MD (LTMD) spanning
the critical period (P19-P33), the deprived eye was reopened (>1 month) until VEP acuity
was measured in V1 (>P60). For AChEI experiments, daily injections were made starting at
P45. (B) Averaged VEP traces (left, mean ± sem; scale: 20 µV, 0.1 sec) and amplitudes
(right) of first negative peak (mean ± sem) reveal acuity recovery after reopening an eye
(blue, 6 mice) initially deprived during the critical period (grey, 5 mice). (C) Visual acuity
in WT mice (white bars) without deprivation (no MD: 0.48 ± 0.03 cyc/deg, 6 mice)
decreases after LTMD spanning the critical period (LTMD: 0.28 ± 0.01 cyc/deg, 3 mice)
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and endures (+eye open: 0.30 ± 0.02 cyc/deg, 5 mice; vs LTMD, P > 0.45; vs no MD, P <
0.0005, t-test). In contrast, reopening the deprived eye together with cholinesterase inhibitor
restores vision (grey bar, AChEI: 0.48 ± 0.06 cyc/deg, 4 mice; vs WT + eye open, * P <
0.05; vs WT no MD + AChEI: 0.47 ± 0.02 cyc/deg, 6mice, P > 0.8, t-test). Lynx1 KO mice
(black bars) spontaneously recover from LTMD (0.28 ± 0.03 cyc/deg, 5 mice) simply by
reopening the deprived eye (0.56 ± 0.02 cyc/deg, 6 mice; *** P < 0.0001, t-test) to reach
normal levels (no MD: 0.56 ± 0.04 cyc/deg, 3 mice).
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Lynx1 may adjust cortical excitatory-inhibitory balance to regulate adult plasticity. (A) In
WT animals (left), mature excitatory-inhibitory balance is maintained by lynx1 that limits
nAChR response. In lynx1 KO mice (right), enhanced nAChR signaling may lead to
excitatory-inhibitory imbalance and adult plasticity, which could be sensitive to acute
restoration of inhibition with diazepam (DZ). (B) Double in situ hybridization of lynx1
(green) with GAD65 (red, upper panel) or parvalbumin (PV, lower panel) in adult V1 (left).
Scale, 100µm. Quantification of overlapping pixels (right) indicates selective expression of
lynx1 in a subset (40%) of GAD65-positive interneurons, most likely PV-positive cells (>
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90% co-localization). (C) Focal diazepam infusion during adult MD in lynx1 KO mice
abolishes ocular dominance plasticity (black, DZ: CBI = 0.67, 6 mice vs grey, vehicle: CBI
= 0.54, 14 mice; *** P < 0.001, t-test). Dark circles represent cortical mini-pump infusion.
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